Vascular Medicine News

Elucid announced it received 510(k) clearance from the FDA for its noninvasive imaging analysis software to help quantify and classify plaque morphology and diagnose CVD.

The FDA approved 18F flurpiridaz, a new cardiac PET perfusion radiotracer, for adult patients with known or suspected coronary artery disease being evaluated for myocardial ischemia and infarction.

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.

A 3-month intervention that decreased sedentary behavior and increased standing during the workday did not reduce BP or arterial stiffness among desk workers with untreated elevated or high BP, according to a study published in Circulation.

Women with obesity and atherosclerotic CVD without diabetes experience fewer CV events vs. men enrolled in the SELECT trial; however, semaglutide was linked to significant reductions in CV events regardless of sex, a speaker reported.

Adults with primary aldosteronism had improvements in disease severity after undergoing an adrenalectomy, according to findings published in Endocrine Practice.

Optimal heart health during the first trimester of pregnancy was associated with lower risk for hypertensive disorders of pregnancy, a speaker reported.

The FDA approved the SPIRARE II trial set to evaluate the use of Jupiter Endovascular’s Vertex Pulmonary Embolectomy System with Endoportal Control in patients with acute pulmonary embolism, according to a press release.

Hospital admissions for heart attack increased after exposure to lower air temperature and cold spells, researchers reported at the European Society of Cardiology Congress.

Shockwave Medical announced the FDA clearance and full U.S. launch of its peripheral intravascular lithotripsy catheter designed to treat calcified femoropopliteal and below-the-knee peripheral artery disease.